CM
KURA icon

Crestline Management’s Kura Oncology KURA Stock Holding History

Crestline Management’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-49,121
Closed -$894K – 195
2018
Q2 		$894K Buy
+49,121
New +$832K 0.09% 204

Other funds holding KURA

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Crestline Management's KURA Position: Q3 2018 in Review

Crestline Management sold out of Kura Oncology (KURA) in Q3 2018, closing a stake of 49,121 shares — an estimated $894K sold.

Crestline Management first reported a position in KURA in Q2 2018 and held it in 1 quarter. The position peaked at $894K in Q2 2018. 116 funds tracked by Wall St. Rank hold KURA as of Q3 2018.

  • Crestline Management reported no remaining Kura Oncology position as of Q3 2018 after selling out during the quarter.
  • Crestline Management sold 49,121 Kura Oncology shares in Q3 2018, an estimated $894K.
  • Crestline Management first reported a position in Kura Oncology in Q2 2018 and held it in 1 quarter.
  • Crestline Management's Kura Oncology position peaked at $894K in Q2 2018.
  • 116 funds tracked by Wall St. Rank held Kura Oncology as of Q3 2018.

Based on Crestline Management's 13F filing for Q3 2018, filed 14 Nov 2018.